Report an error

Spotted something inaccurate in “Oral PCSK9 Inhibitor Enlicitide Achieves 59% Greater LDL Reduction Than Placebo in Phase 3 HeFH Trial”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.